Induced humoral immunity of different types of vaccines against most common variants of SARS-CoV-2 in Egypt prior to Omicron outbreak

Vaccine. 2022 Jul 30;40(32):4303-4306. doi: 10.1016/j.vaccine.2022.05.086. Epub 2022 Jun 6.

Abstract

The diversity of SARS-CoV-2 continues to lead to the emergence of new SARS-CoV-2 variants. SARS-CoV-2 antibody assays are crucial in managing the COVID-19 pandemic by determining the neutralizing antibody response. This study aims to investigate vaccine-induced antibodies against most common variants of SARS-CoV-2 in Egypt. Sera samples were collected from vaccinated participants and neutralizing activity against the SARS-CoV-2 variants was determined using microneutralization assay. Our results show that the BNT162b2 (Pfizer-BioNTech), ChAdOx1 nCov-19 (AstraZeneca), and Ad26.COV2.S COVID-19 (Janssen) vaccines elicited neutralizing antibody responses more than the BBIBP-CorV vaccine (Sinopharm) against B.1, C.36.3, and AY.32 (Delta) variants. While vaccines remain highly effective in managing the COVID-19 pandemic, ongoing monitoring of vaccine effectiveness is needed.

Keywords: COVID-19 pandemic; Microneutralization assay; Neutralizing antibodies; SARS-CoV-2; SARS-CoV-2 vaccine; Vaccine effectiveness.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Ad26COVS1
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • BNT162 Vaccine
  • COVID-19* / epidemiology
  • COVID-19* / prevention & control
  • ChAdOx1 nCoV-19
  • Egypt / epidemiology
  • Humans
  • Immunity, Humoral
  • Pandemics
  • SARS-CoV-2*

Substances

  • Ad26COVS1
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • ChAdOx1 nCoV-19
  • BNT162 Vaccine

Supplementary concepts

  • SARS-CoV-2 variants